125 related articles for article (PubMed ID: 12925107)
1. Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers.
Lubasch A; Ziege S; Brodersen B; Borner K; Koeppe P; Lode H
Clin Microbiol Infect; 2003 Jul; 9(7):670-7. PubMed ID: 12925107
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
McNabb J; Quintiliani R; Nightingale CH; Nicolau DP
Chemotherapy; 2000; 46(6):383-9. PubMed ID: 11053903
[TBL] [Abstract][Full Text] [Related]
3. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Burgess DS; Hastings RW
Diagn Microbiol Infect Dis; 2000 Sep; 38(1):37-41. PubMed ID: 11025182
[TBL] [Abstract][Full Text] [Related]
4. Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivo.
Mimoz O; Jacolot A; Padoin C; Caillon J; Louchahi K; Tod M; Samii K; Petitjean O
J Antimicrob Chemother; 1997 Mar; 39(3):363-9. PubMed ID: 9096186
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains.
Bantar C; Di Chiara M; Nicola F; Relloso S; Smayevsky J
Diagn Microbiol Infect Dis; 2000 May; 37(1):41-4. PubMed ID: 10794939
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin.
Milatovic D; Wallrauch C
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):688-93. PubMed ID: 8894583
[TBL] [Abstract][Full Text] [Related]
7. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
Prieto J; Aguilar L; Fuentes F; Giménez MJ; Alou L; Dal-Ré R; Sörgel F; Frías J
Int J Antimicrob Agents; 2001 Sep; 18(3):231-8. PubMed ID: 11673035
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial properties of gemifloxacin and trovafloxacin in urine ex vivo: phase I study.
García-Calvo G; Parra A; Aguilar L; Ponte C; Giménez MJ; Carcas A; Kinzig-Schippers M; Soriano F
Antimicrob Agents Chemother; 2001 Jun; 45(6):1876-8. PubMed ID: 11353641
[TBL] [Abstract][Full Text] [Related]
9. [In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model].
Elkhaïli H; Pompei D; Peter JD; Linger L; Salmon J; Levêque D; Niedergang S; Salmon Y; Thierry RC; Monteil H; Jehl F
Pathol Biol (Paris); 1997 May; 45(5):347-56. PubMed ID: 9296083
[TBL] [Abstract][Full Text] [Related]
10. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.
Mimoz O; Jacolot A; Padoin C; Tod M; Samii K; Petitjean O
J Antimicrob Chemother; 1998 Mar; 41(3):367-72. PubMed ID: 9578163
[TBL] [Abstract][Full Text] [Related]
11. Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Aeschlimann JR; Hershberger E; Rybak MJ
Antimicrob Agents Chemother; 2000 May; 44(5):1153-8. PubMed ID: 10770744
[TBL] [Abstract][Full Text] [Related]
12. [Kinetics of bactericidal activity of cefepime and cefpirome alone or combined with gentamicin, amikacin or ciprofloxacin against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae hyperproductive in cephalosporinase].
Elkhaïli H; Pompei D; Linger L; Kamili N; Monteil H; Jehl F
Pathol Biol (Paris); 1996 May; 44(5):367-73. PubMed ID: 8758478
[TBL] [Abstract][Full Text] [Related]
13. Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae.
Van Laethem Y; Lagast H; Klastersky J
Antimicrob Agents Chemother; 1983 Mar; 23(3):435-9. PubMed ID: 6221694
[TBL] [Abstract][Full Text] [Related]
14. Oral bioavailability of trovafloxacin with and without food in healthy volunteers.
Teng R; Dogolo LC; Willavize SA; Friedman HL; Vincent J
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():87-92. PubMed ID: 9222076
[TBL] [Abstract][Full Text] [Related]
15. An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin.
Purkins L; Oliver SD; Willavize SA
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):431-3. PubMed ID: 9758288
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin.
Van der Auwera P; Klastersky J; Lieppe S; Husson M; Lauzon D; Lopez AP
Antimicrob Agents Chemother; 1986 Feb; 29(2):230-4. PubMed ID: 3087276
[TBL] [Abstract][Full Text] [Related]
17. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Zhao C; Xie W; Zhang W; Ye Z; Wu H
Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
[TBL] [Abstract][Full Text] [Related]
18. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
[TBL] [Abstract][Full Text] [Related]
19. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
[TBL] [Abstract][Full Text] [Related]
20. Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.
Fitoussi F; Doit C; Geslin P; Bingen E
Antimicrob Agents Chemother; 1999 Oct; 43(10):2372-5. PubMed ID: 10508009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
